NLRP3 and gout: There were several publications that indicated that luteolin, luteoloside, and apigenin inhibited NLRP3 activation in rodents (Fan et al., 2014; Lv et al., 2019; Wang, X. et al., 2021); however, to the best of our knowledge, the present study is the first research that investigates the involvement of NLRP3 inhibition in the anti-gouty arthritis effects of luteolin, luteoloside, and apigenin.